Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
Clicks: 121
ID: 274183
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.0
/100
20 views
20 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates.Week 6 vedolizumab responders were re-randomized ...
| Reference Key |
lasch2019journaldeep
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | William J Sandborn, Jean-Frédéric Colombel, Remo Panaccione, Parambir S Dulai, Maria Rosario, Charlie Cao, Morris Barocas, Karen Lasch;William J Sandborn;Jean-Frédéric Colombel;Remo Panaccione;Parambir S Dulai;Maria Rosario;Charlie Cao;Morris Barocas;Karen Lasch; |
| Journal | journal of crohn's & colitis |
| Year | 2019 |
| DOI |
10.1093/ecco-jcc/jjy149
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.